ScinoPharm Taiwan (1789) Q1 2026 EPS: NT$0.02
NQ Score
0/100
N1 Content Completeness
3
AI Summary (NQ-processed)
ScinoPharm Taiwan announced its Q1 2026 financial results, with consolidated EPS of NT$0.02, operating revenue of NT$660 million, and after-tax net profit of NT$17 million. This reflects the latest financial status of the company in the biotechnology and healthcare industry.